[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diarrhea-predominant-irritable-bowel-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diarrhea-predominant-irritable-bowel-syndrome":96},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100646766","phase-3-clinical-efficacy-and-safety-of-jingfang-granules-in-treating-diarrhea-predominant-irritable-bowel-syndrome-with-cold-dampness-disturbing-spleen-syndrome-100646766",false,"NCT07688161","Clinical Efficacy and Safety of Jingfang Granules in Treating Diarrhea-Predominant Irritable Bowel Syndrome With Cold-Dampness Disturbing Spleen Syndrome","Inclusion Criteria:\n\n1. Meet the Western medicine diagnostic criteria for diarrhea-predominant irritable bowel syndrome (IBS-D) (IBS symptoms lasting for at least 6 months, and meeting the Rome IV criteria in the past 3 months) and the traditional Chinese medicine diagnostic criteria for cold-dampness disturbing spleen syndrome;\n2. Aged between 18 and 65 years, with no gender restriction;\n3. Baseline IBS-SSS score ≥ 75;\n4. No use of any medication for irritable bowel syndrome for at least 1 week before entering treatment;\n5. Subjects are informed and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with severe cardiovascular, respiratory, liver, kidney, or other major organ diseases, diabetes, tumors, hematopoietic system disorders, nervous system diseases, or psychiatric disorders;\n2. Patients with other organic digestive system diseases (e.g., peptic ulcer) or systemic diseases affecting gastrointestinal motility (e.g., hyperthyroidism, diabetes mellitus);\n3. Patients currently using or requiring continuous use of medications that may affect gastrointestinal function (e.g., antidiarrheals, antidepressants, anxiolytics, intestinal microbiota regulators, antibiotics, etc.);\n4. Patients who have taken antibiotics, steroids or other hormones, herbal preparations (including oral and intravenous), microecological preparations, or probiotics (such as yogurt) within the past 1 week;\n5. Patients who have previously undergone abdominal or anorectal surgery;\n6. Pregnant or breastfeeding women;\n7. Patients with a history of allergy to relevant drugs or severe food allergy;\n8. Patients who have participated in or are currently participating in other interventional clinical research studies within the past 3 months;\n9. Patients who refuse to enroll in the observation or have other unstable factors, such as failure to take medication as prescribed, or taking other medications that affect the evaluation of efficacy, leading to inability to determine treatment effects, or incomplete data.","ALL","18 Years","65 Years",{"count":19,"type":20},106,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This prospective, open-label, randomized controlled clinical trial aims to evaluate the clinical efficacy and safety of Jingfang Granules in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D) with cold-dampness encumbering the spleen syndrome, and to explore its potential mechanisms of action. A total of 106 patients with IBS-D of cold-dampness encumbering the spleen syndrome are planned to be enrolled and randomly assigned to the experimental group and the control group, with 53 patients in each group. The treatment will last for 4 weeks, followed by a 12-week follow-up period. The primary outcome measure is the IBS Severity Scoring System (IBS-SSS). Secondary outcomes include the Traditional Chinese Medicine (TCM) syndrome score, the Bristol Stool Form Scale, patient-reported outcome (PRO) scales, the IBS Quality of Life (IBS-QOL) questionnaire, recurrence rate, and others. Exploratory measures, such as immune-inflammatory cytokines and biomarkers related to intestinal mucosal barrier function, will also be observed.",[26],"Diarrhea-predominant Irritable Bowel Syndrome","NOT_YET_RECRUITING","2026-06-30",{"date":30,"type":31},"2026-07-07","ACTUAL",{"date":33,"type":20},"2026-07",{"date":35,"type":20},"2028-02",{"name":37,"class":38},"Nanjing First Hospital, Nanjing Medical University","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":39},"100592972","evaluation-of-the-efficacy-and-safety-of-gelsectan-in-the-treatment-of-diarrhea-predominant-irritable-bowel-syndrome-100592972","NCT07000383","Evaluation of the Efficacy and Safety of Gelsectan in the Treatment of Diarrhea-predominant Irritable Bowel Syndrome","Evaluation of the Efficacy and Safety of Gelsectan in the Treatment of Diarrhea-predominant Irritable Bowel Syndrome at University Medical Center Ho Chi Minh City, Vietnam: a Randomized, Open-label Clinical Trial","GELIBS","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of IBS-D based on the Rome IV criteria,8 including:\n\n  * Recurrent abdominal pain occurring at least one day per week in the last three months, associated with at least two of the following: related to defecation, associated with a change in stool frequency, or associated with a change in stool form. These criteria must have been present during the last three months, with symptom onset at least six months prior to diagnosis;\n  * More than 25% of bowel movements with stool types 6 or 7 and less than 25% with stool types 1 or 2 according to the Bristol Stool Form Scale.\n* Signed informed consent for study participation\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Known allergy to any component of the study medication\n* Diagnosed with diabetes mellitus\n* Patients with severe comorbidities or psychiatric disorders that impair their ability to complete questionnaires or attend follow-up visits",{"count":49,"type":20},90,[51],"NA","This clinical study aims to investigate the effectiveness and safety of Gelsectan, a treatment containing xyloglucan, in adults diagnosed with diarrhea-predominant irritable bowel syndrome (IBS-D) in Vietnam. IBS-D is a common digestive disorder that causes frequent diarrhea along with abdominal pain and bloating, significantly affecting patients' daily life and wellbeing.\n\nThe main goal of the study is to determine whether Gelsectan can reduce the severity of symptoms such as diarrhea, abdominal discomfort, and bloating, and improve patients' quality of life. Participants will be randomly assigned to receive either Gelsectan alone, Gelsectan combined with an antispasmodic medication, or antispasmodic medication alone. The treatment will last for two months, with regular monitoring of symptom changes and any side effects.\n\nThe investigators hypothesize that Gelsectan treatment will lead to better symptom relief and quality of life compared to standard antispasmodic treatment. The study will also carefully observe the safety profile of Gelsectan during the treatment period.\n\nResults from this study will provide important information about the potential benefits and risks of Gelsectan for Vietnamese patients with IBS-D and may contribute to improving treatment options for this condition in Vietnam.",[26,54],"Irritable Bowel Syndrome of Diarrhea Type (IBS-D)",[56,57,58,59,60,61,46],"Irritable Bowel Syndrome","Gelsectan","Diarrhea-Predominant Irritable Bowel Syndrome","IBS-D","Irritable Bowel Syndrome of Diarrhea type","Xyloglucan","RECRUITING","2026-05-22",{"date":65,"type":31},"2026-05-27",{"date":67,"type":31},"2025-06-15",{"date":69,"type":20},"2026-07-31",{"name":71,"class":38},"University Medical Center Ho Chi Minh City (UMC)",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":15,"minAge":16,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":39},"100572776","phase-1-study-on-the-effectiveness-and-mechanism-of-tong-xie-yao-fang-in-treating-diarrhea-predominant-irritable-bowel-syndrome-100572776","NCT06737666","Study on the Effectiveness and Mechanism of Tong-Xie-Yao-Fang in Treating Diarrhea-predominant Irritable Bowel Syndrome","Effects of Tong-Xie-Yao-Fang in Regulating Treg\u002FTh17 Imbalance of Diarrhea-predominant Irritable Bowel Syndrome by Trp-Kyn-AhR Pathway","Inclusion Criteria:\n\n* IBS-D patients and healthy volunteers meeting diagnostic criteria;\n* Aged between 18 and 70;\n* Have not taken antibiotics, steroids and other hormones, Chinese herbal preparations (including oral and intravenous injections), microecological preparations or probiotics such as yogurt in the past week.\n* Patients sign informed consent forms and are willing to receive appropriate treatment, and volunteers are willing to cooperate in taking blood, urine, stool and other samples.\n\nExclusion Criteria:\n\n* Patients with serious heart, liver, kidney and other major organ diseases, hematopoietic system, nervous system or mental diseases;\n* Other organic diseases of the digestive system (such as peptic ulcers), organic diseases such as tumors indicated by recent colonoscopy, or systemic diseases affecting digestive motility (such as hyperthyroidism, diabetes);\n* Need to continue to use drugs that may affect gastrointestinal function (antidiarrheals, antidepressants, anti-anxiety drugs, intestinal flora regulation drugs, antibiotics, etc.);\n* Have a history of drug allergy or severe food allergy for research purposes;\n* Patients under 18 years of age or over 75 years of age and pregnant or lactating women;\n* Severe negative life events occurred during treatment;\n* There is currently any form of psychotherapy in progress;\n* No intention to cooperate.",true,"70 Years",{"count":82,"type":20},60,[84],"PHASE1","Traditional Chinese Medicine focuses on the main pathogenesis of liver depression and spleen deficiency, and treats them from the perspective of soothing the liver and strengthening the spleen to treat on Diarrhea-predominant irritable bowel syndrome (IBS-D) . The classic formula for treating is the Tong-Xie-Yao-Fang (TXYF). Based on metabolomics and metagenomics, the research group studied the intestinal flora and host co metabolism of TXYF in the treatment of diarrhea predominant IBS-D, in order to clarify the mechanism of TXYF in the treatment of IBS-D.",[26],"2024-12-15",{"date":89,"type":31},"2024-12-17",{"date":91,"type":31},"2023-05-29",{"date":93,"type":20},"2025-12",{"name":95,"class":38},"Xiyuan Hospital of China Academy of Chinese Medical Sciences","Diarrhea Predominant Irritable Bowel Syndrome"]